Luoxin Pharmaceutical's LX-039 : Phase I Clinical Study Data Presented at ESMO 2023

Luoxin Pharmaceutical Group Stock Co., Ltd. Spain China

View original content:https://www.prnewswire.co.uk/news-releases/luoxin-pharmaceuticals-lx-039-innovative-anti-tumor-drug-phase-i-clinical-study-data-presented-at-esmo-2023-301964360.html